Codexis Inc (CDXS, Financial) files its latest 10-K with SEC for the fiscal year ended on December 31, 2017. Codexis Inc is a biotech company. It develops proprietary biocatalysts-enzymes or microbes that initiate or accelerate chemical reactions. It offers its products to the pharmaceutical industry. The company also develops advanced biofuels. Codexis Inc has a market cap of $584.990 million; its shares were traded at around $12.10 with and P/S ratio of 14.05. Codexis Inc had annual average EBITDA growth of 22.30% over the past five years.
For the last quarter Codexis Inc reported a revenue of $21.7 million, compared with the revenue of $9.97 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $50.0 million, an increase of 2.4% from last year. For the last five years Codexis Inc had an average revenue decline of 3.9% a year.
The reported loss per diluted share was 50 cents for the year, compared with the loss per share of $0.5 in the previous year. The Codexis Inc had an operating margin of -45.92%, compared with the operating margin of -17.54% a year before. The 10-year historical median operating margin of Codexis Inc is -28.36%. The profitability rank of the company is 1 (out of 10).
At the end of the fiscal year, Codexis Inc has the cash and cash equivalents of $31.2 million, compared with $19.2 million in the previous year. The long term debt was $0.30 million. Codexis Inc has a financial strength rank of 7 (out of 10).
At the current stock price of $12.10, Codexis Inc is traded at 395.9% premium to its historical median P/S valuation band of $2.44. The P/S ratio of the stock is 14.05, while the historical median P/S ratio is 2.83. The stock gained 151.65% during the past 12 months.
For the complete 20-year historical financial data of CDXS, click here.
